Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
Vaccine
; 42(15): 3410-3419, 2024 May 31.
Article
em En
| MEDLINE
| ID: mdl-38641498
ABSTRACT
The application of recombinant herpesvirus of turkey, expressing the H9 hemagglutinin gene from low pathogenic avian influenza virus (LPAIV) H9N2 and the avian orthoavulavirus-1 (AOAV-1) (commonly known as Newcastle Disease virus (NDV)) fusion protein (F) as an rHVT-H9-F vaccine, is an alternative to currently used classical vaccines. This study investigated H9- and ND-specific humoral and mucosal responses, H9-specific cell-mediated immunity, and protection conferred by the rHVT-H9-F vaccine in specific pathogen-free (SPF) chickens. Vaccination elicited systemic NDV F- and AIV H9-specific antibody response but also local antibodies in eye wash fluid and oropharyngeal swabs. The ex vivo H9-specific stimulation of splenic and pulmonary T cells in the vaccinated group demonstrated the ability of vaccination to induce systemic and local cellular responses. The clinical protection against a challenge using a LPAIV H9N2 strain of the G1 lineage isolated in Morocco in 2016 was associated with a shorter duration of shedding along with reduced viral genome load in the upper respiratory tract and reduced cloacal shedding compared to unvaccinated controls.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Vacinas contra Influenza
/
Galinhas
/
Eliminação de Partículas Virais
/
Vírus da Influenza A Subtipo H9N2
/
Influenza Aviária
/
Anticorpos Antivirais
Limite:
Animals
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2024
Tipo de documento:
Article